01—Abstract
Summary
Summary of the 8-K filed September 9, 2024. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly announced on September 9, 2024 that Lucas Montarce, a 25-year Lilly veteran, has been appointed executive vice president and chief financial officer, effective immediately, and joins the Executive Committee.
He follows a competitive search across health care, tech and general industries. Montarce most recently served as Lilly president and general manager for the Spain, Portugal and Greece hub, and previously led finance at Lilly Research Laboratories (as controller and CFO), Lilly International, and Elanco Health. The filing is a leadership transition rather than a financial disclosure, so it contains no earnings, guidance, or balance sheet data.
Compensation is modest relative to the company's scale: an annualized base salary of $1,000,000a and an annualized target bonus of $1,000,000. The filing states there are no arrangements under which he was selected, no family relationships with directors or executive officers, and no related-party transactions under Item 404(a) of Regulation S-K. CEO David Ricks publicly expressed high confidence in Montarce, citing more than a decade of working directly with him.
For investors, the key takeaway is continuity and an internally developed successor. Montarce's background spans finance, controllership, and international operations, which aligns with Lilly's expanding global footprint and its focus on long-term value creation. The filing itself does not indicate any change in strategy or financial outlook.
02—Key points
Key Highlights
- Lucas Montarce appointed EVP and CFO effective September 9, 2024, and named to the Executive Committee
- Montarce has been with Lilly since 2001 and most recently led the Spain, Portugal and Greece hub
- Prior roles include CFO of Lilly Research Laboratories, CFO of Lilly International, and global CFO of Elanco Health
- Compensation: $1,000,000 annualized base salary and $1,000,000 annualized target bonus
- Selection followed an internal and external search across health care, tech and general industries
- No related-party transactions, family relationships, or arrangements under which he was selected
- CEO David Ricks cited more than a decade of direct work with Montarce as the basis for confidence in his leadership
03—Questions
Frequently Asked Questions
Who is the new CFO of Eli Lilly and what is his background?
Lucas Montarce, age 47, joined Lilly in 2001 and has held multiple finance leadership roles, including controller and CFO of Lilly Research Laboratories, CFO of Lilly International, and global CFO of Elanco Health. Most recently he was president and general manager for the Spain, Portugal and Greece hub.
Is the CFO change effective immediately?
Yes. The appointment is effective immediately as of September 9, 2024, per the company's announcement and the 8-K filing.
What is Montarce's compensation?
He will receive an annualized base salary of $1,000,000 and is eligible for an annualized target bonus of $1,000,000. The filing does not disclose equity awards or other compensation elements in this document.
Does this filing include any financial results or guidance changes?
No. The 8-K covers only the executive appointment and an accompanying press release. It contains no earnings, revenue, guidance, or balance sheet information.
Was Montarce selected under any special arrangement or does he have related-party ties?
The filing states there are no arrangements or understandings under which he was selected, no family relationship with any director or executive officer, and no transactions subject to Item 404(a) of Regulation S-K.
04—Continue